多替阿巴拉米片在国内上市了吗？

On August 1, 2017, GlaxoSmithKline (GSK) announced that its joint venture ViiV Healthcare’s single-pill compound preparation Suimeikai (chemical name: Suimeikan) with the new generation integrase inhibitor Tevicai (chemical name: dolutegravir) as the core for the treatment of HIV was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. As an innovative single-tablet compound preparation with obvious clinical therapeutic advantages, Dolutegra Abalamid Tablets can provide great convenience for the treatment of HIV-infected patients.

Dolutegravir tablets are the only three-in-one compound drug with dolutegravir (DTG) as the core. It has the characteristics of high efficacy, good tolerability, high resistance barrier, and few drug interactions. One tablet per day can significantly reduce the medication burden of HIV-infected patients, thereby improving patients' medication compliance and significantly improving their quality of life.

Professor Zhang Fujie, Director of the Infection Clinical and Research Center of Beijing Ditan Hospital of Capital Medical University, said: "Currently, global antiviral treatment is gradually entering the era of integrase inhibitors, and fixed-dose compound preparations have also become a trend in future treatment. Integrase inhibitors have stronger antiviral effects, smaller toxic side effects, and fewer The four main features of Suimeikai are that it has fewer drug interactions and is less prone to drug resistance. As a single-pill compound drug containing a new generation of integrase inhibitor DTG, its launch will bring a more convenient and efficient integrase inhibitor compound combination to Chinese HIV-infected patients, which is a major advancement in China’s existing antiviral treatment.”

Mr. Wei Liansheng, General Manager of GSK China's Prescription Drugs and Vaccines Division, said: "Improving the accessibility of our innovative drugs is a clear strategy for us to fulfill our commitment to 'Be based in China, work with China, and serve China'. We are pleased to announce that Suimeike is now available in the Chinese mainland market, providing another innovative treatment option for people living with HIV. We are cooperating with multiple organizations to carry out multiple projects including AIDS medical personnel training, disease prevention and education, so that people living with HIV can receive better support and help."

Following the launch of Tivicai, a new HIV treatment drug last year, this is another new HIV drug from GSK approved for sale in mainland China. Currently, it has been approved for marketing in 50 countries and regions, and has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line first-line treatment for patients with HIV infection.